U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Platinum-Resistant Head and Neck Carcinoma

MedGen UID:
1791941
•Concept ID:
C5555500
•
Neoplastic Process

Definition

Head and neck carcinoma that is resistant to platinum therapy. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVPlatinum-Resistant Head and Neck Carcinoma

Professional guidelines

PubMed

Paclitaxel-Ifosfamide-based Therapy as Salvage Treatment in Platinum-resistant Recurrent/Metastatic Head and Neck Cancer.
Chou MY, Wu WC, Chu PY, Tai SK, Chang PM, Lee TL, Chen TH, Yang MH
In Vivo 2024 Jul-Aug;38(4):1891-1899. doi: 10.21873/invivo.13644. PMID: 38936932Free PMC Article
Cost-effectiveness of pembrolizumab for treatment of platinum-resistant recurrent or metastatic head and neck squamous cell carcinoma in China: an economic analysis based on a randomised, open-label, phase III trial.
Xin W, Ding H, Fang Q, Zheng X, Tong Y, Xu G, Yang G
BMJ Open 2020 Dec 18;10(12):e038867. doi: 10.1136/bmjopen-2020-038867. PMID: 33371020Free PMC Article
Cost-effectiveness Analysis of Nivolumab for Treatment of Platinum-Resistant Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck.
Tringale KR, Carroll KT, Zakeri K, Sacco AG, Barnachea L, Murphy JD
J Natl Cancer Inst 2018 May 1;110(5):479-485. doi: 10.1093/jnci/djx226. PMID: 29126314Free PMC Article

Recent clinical studies

Etiology

Paclitaxel-Ifosfamide-based Therapy as Salvage Treatment in Platinum-resistant Recurrent/Metastatic Head and Neck Cancer.
Chou MY, Wu WC, Chu PY, Tai SK, Chang PM, Lee TL, Chen TH, Yang MH
In Vivo 2024 Jul-Aug;38(4):1891-1899. doi: 10.21873/invivo.13644. PMID: 38936932Free PMC Article
Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial.
Sacco AG, Chen R, Worden FP, Wong DJL, Adkins D, Swiecicki P, Chai-Ho W, Oppelt P, Ghosh D, Bykowski J, Molinolo A, Pittman E, Estrada MV, Gold K, Daniels G, Lippman SM, Natsuhara A, Messer K, Cohen EEW
Lancet Oncol 2021 Jun;22(6):883-892. Epub 2021 May 11 doi: 10.1016/S1470-2045(21)00136-4. PMID: 33989559
Immunotherapy in head and neck cancer: aiming at EXTREME precision.
Szturz P, Vermorken JB
BMC Med 2017 Jun 2;15(1):110. doi: 10.1186/s12916-017-0879-4. PMID: 28571578Free PMC Article
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, Erfan J, Zabolotnyy D, Kienzer HR, Cupissol D, Peyrade F, Benasso M, Vynnychenko I, De Raucourt D, Bokemeyer C, Schueler A, Amellal N, Hitt R
N Engl J Med 2008 Sep 11;359(11):1116-27. doi: 10.1056/NEJMoa0802656. PMID: 18784101
Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.
Fossella FV, DeVore R, Kerr RN, Crawford J, Natale RR, Dunphy F, Kalman L, Miller V, Lee JS, Moore M, Gandara D, Karp D, Vokes E, Kris M, Kim Y, Gamza F, Hammershaimb L
J Clin Oncol 2000 Jun;18(12):2354-62. doi: 10.1200/JCO.2000.18.12.2354. PMID: 10856094

Diagnosis

Both combined or sequential use with immune checkpoint inhibitors on cetuximab-treated patients with recurrent or metastatic head and neck squamous cell carcinoma improve the overall survival.
Lien MY, Wang TH, Hsieh CY, Tsai MH, Hua CH, Cheng FM, Chung WH, Tang CH, Chia-Hsun Hsieh J
Oral Oncol 2021 Aug;119:105380. Epub 2021 Jun 17 doi: 10.1016/j.oraloncology.2021.105380. PMID: 34146822
ACTL6A promotes repair of cisplatin-induced DNA damage, a new mechanism of platinum resistance in cancer.
Xiao Y, Lin FT, Lin WC
Proc Natl Acad Sci U S A 2021 Jan 19;118(3) doi: 10.1073/pnas.2015808118. PMID: 33408251Free PMC Article
Cost-effectiveness of pembrolizumab for treatment of platinum-resistant recurrent or metastatic head and neck squamous cell carcinoma in China: an economic analysis based on a randomised, open-label, phase III trial.
Xin W, Ding H, Fang Q, Zheng X, Tong Y, Xu G, Yang G
BMJ Open 2020 Dec 18;10(12):e038867. doi: 10.1136/bmjopen-2020-038867. PMID: 33371020Free PMC Article
Clinical outcomes of platinum-based chemotherapy plus cetuximab for recurrent or metastatic squamous cell carcinoma of the head and neck: comparison between platinum-sensitive and platinum-resistant patients.
Sato H, Tsukahara K, Okamoto I, Katsube Y, Shimizu A, Kondo T, Hanyu K, Fushimi C, Okada T, Miura K
Acta Otolaryngol 2019 Feb;139(2):201-205. Epub 2019 Feb 22 doi: 10.1080/00016489.2018.1551623. PMID: 30794080
CHK1 Inhibition in Small-Cell Lung Cancer Produces Single-Agent Activity in Biomarker-Defined Disease Subsets and Combination Activity with Cisplatin or Olaparib.
Sen T, Tong P, Stewart CA, Cristea S, Valliani A, Shames DS, Redwood AB, Fan YH, Li L, Glisson BS, Minna JD, Sage J, Gibbons DL, Piwnica-Worms H, Heymach JV, Wang J, Byers LA
Cancer Res 2017 Jul 15;77(14):3870-3884. Epub 2017 May 10 doi: 10.1158/0008-5472.CAN-16-3409. PMID: 28490518Free PMC Article

Therapy

Paclitaxel-Ifosfamide-based Therapy as Salvage Treatment in Platinum-resistant Recurrent/Metastatic Head and Neck Cancer.
Chou MY, Wu WC, Chu PY, Tai SK, Chang PM, Lee TL, Chen TH, Yang MH
In Vivo 2024 Jul-Aug;38(4):1891-1899. doi: 10.21873/invivo.13644. PMID: 38936932Free PMC Article
Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial.
Sacco AG, Chen R, Worden FP, Wong DJL, Adkins D, Swiecicki P, Chai-Ho W, Oppelt P, Ghosh D, Bykowski J, Molinolo A, Pittman E, Estrada MV, Gold K, Daniels G, Lippman SM, Natsuhara A, Messer K, Cohen EEW
Lancet Oncol 2021 Jun;22(6):883-892. Epub 2021 May 11 doi: 10.1016/S1470-2045(21)00136-4. PMID: 33989559
CHK1 Inhibition in Small-Cell Lung Cancer Produces Single-Agent Activity in Biomarker-Defined Disease Subsets and Combination Activity with Cisplatin or Olaparib.
Sen T, Tong P, Stewart CA, Cristea S, Valliani A, Shames DS, Redwood AB, Fan YH, Li L, Glisson BS, Minna JD, Sage J, Gibbons DL, Piwnica-Worms H, Heymach JV, Wang J, Byers LA
Cancer Res 2017 Jul 15;77(14):3870-3884. Epub 2017 May 10 doi: 10.1158/0008-5472.CAN-16-3409. PMID: 28490518Free PMC Article
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, Erfan J, Zabolotnyy D, Kienzer HR, Cupissol D, Peyrade F, Benasso M, Vynnychenko I, De Raucourt D, Bokemeyer C, Schueler A, Amellal N, Hitt R
N Engl J Med 2008 Sep 11;359(11):1116-27. doi: 10.1056/NEJMoa0802656. PMID: 18784101
Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.
Fossella FV, DeVore R, Kerr RN, Crawford J, Natale RR, Dunphy F, Kalman L, Miller V, Lee JS, Moore M, Gandara D, Karp D, Vokes E, Kris M, Kim Y, Gamza F, Hammershaimb L
J Clin Oncol 2000 Jun;18(12):2354-62. doi: 10.1200/JCO.2000.18.12.2354. PMID: 10856094

Prognosis

Paclitaxel-Ifosfamide-based Therapy as Salvage Treatment in Platinum-resistant Recurrent/Metastatic Head and Neck Cancer.
Chou MY, Wu WC, Chu PY, Tai SK, Chang PM, Lee TL, Chen TH, Yang MH
In Vivo 2024 Jul-Aug;38(4):1891-1899. doi: 10.21873/invivo.13644. PMID: 38936932Free PMC Article
Revisiting the concept of neoadjuvant and induction therapy in head and neck cancer with the advent of immunotherapy.
Smussi D, Mattavelli D, Paderno A, Gurizzan C, Lorini L, Romani C, Bignotti E, Grammatica A, Ravanelli M, Bossi P
Cancer Treat Rev 2023 Dec;121:102644. Epub 2023 Oct 12 doi: 10.1016/j.ctrv.2023.102644. PMID: 37862833
Tumor Mutational Burden as a Predictor of Survival with Durvalumab and/or Tremelimumab Treatment in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
Wildsmith S, Li W, Wu S, Stewart R, Morsli N, Raja R, Zhang Q, Ye J, He P, Shetty J, Yovine A, Holoweckyj N, Real K, Walker J, Wrona M, de Los Reyes M, Barker C, Whiteley J, Haddad R, Licitra L, Ferris R, Fayette J, Zandberg DP, Siu LL, Mesía R
Clin Cancer Res 2023 Jun 1;29(11):2066-2074. doi: 10.1158/1078-0432.CCR-22-2765. PMID: 36806911Free PMC Article
A retrospective analysis of tumor infiltrating lymphocytes in head and neck squamous cell carcinoma patients treated with nivolumab.
Kuba K, Inoue H, Matsumura S, Enoki Y, Kogashiwa Y, Ebihara Y, Nakahira M, Yamazaki T, Yasuda M, Kaira K, Kagamu H, Sugasawa M
Sci Rep 2022 Dec 29;12(1):22557. doi: 10.1038/s41598-022-27237-0. PMID: 36581686Free PMC Article
CHK1 Inhibition in Small-Cell Lung Cancer Produces Single-Agent Activity in Biomarker-Defined Disease Subsets and Combination Activity with Cisplatin or Olaparib.
Sen T, Tong P, Stewart CA, Cristea S, Valliani A, Shames DS, Redwood AB, Fan YH, Li L, Glisson BS, Minna JD, Sage J, Gibbons DL, Piwnica-Worms H, Heymach JV, Wang J, Byers LA
Cancer Res 2017 Jul 15;77(14):3870-3884. Epub 2017 May 10 doi: 10.1158/0008-5472.CAN-16-3409. PMID: 28490518Free PMC Article

Clinical prediction guides

Paclitaxel-Ifosfamide-based Therapy as Salvage Treatment in Platinum-resistant Recurrent/Metastatic Head and Neck Cancer.
Chou MY, Wu WC, Chu PY, Tai SK, Chang PM, Lee TL, Chen TH, Yang MH
In Vivo 2024 Jul-Aug;38(4):1891-1899. doi: 10.21873/invivo.13644. PMID: 38936932Free PMC Article
Tumor Mutational Burden as a Predictor of Survival with Durvalumab and/or Tremelimumab Treatment in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
Wildsmith S, Li W, Wu S, Stewart R, Morsli N, Raja R, Zhang Q, Ye J, He P, Shetty J, Yovine A, Holoweckyj N, Real K, Walker J, Wrona M, de Los Reyes M, Barker C, Whiteley J, Haddad R, Licitra L, Ferris R, Fayette J, Zandberg DP, Siu LL, Mesía R
Clin Cancer Res 2023 Jun 1;29(11):2066-2074. doi: 10.1158/1078-0432.CCR-22-2765. PMID: 36806911Free PMC Article
A retrospective analysis of tumor infiltrating lymphocytes in head and neck squamous cell carcinoma patients treated with nivolumab.
Kuba K, Inoue H, Matsumura S, Enoki Y, Kogashiwa Y, Ebihara Y, Nakahira M, Yamazaki T, Yasuda M, Kaira K, Kagamu H, Sugasawa M
Sci Rep 2022 Dec 29;12(1):22557. doi: 10.1038/s41598-022-27237-0. PMID: 36581686Free PMC Article
The Potential for Selective Cyclin-Dependent Kinase 4/6 Inhibition in the Therapy for Head and Neck Squamous Cell Carcinoma.
Adkins D, Ley J, Cohen J, Oppelt P
Cancer J 2022 Sep-Oct 01;28(5):377-380. doi: 10.1097/PPO.0000000000000617. PMID: 36165726
Immunotherapy in head and neck cancer: aiming at EXTREME precision.
Szturz P, Vermorken JB
BMC Med 2017 Jun 2;15(1):110. doi: 10.1186/s12916-017-0879-4. PMID: 28571578Free PMC Article

Recent systematic reviews

Systemic Therapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma- A Systematic Review and Meta-Analysis.
Lau A, Yang WF, Li KY, Su YX
Crit Rev Oncol Hematol 2020 Sep;153:102984. Epub 2020 May 30 doi: 10.1016/j.critrevonc.2020.102984. PMID: 32569853

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Recent activity

    Your browsing activity is temporarily unavailable.